4f

Synthesis of New [[(3-Substituted-5-isoxazolyl-alkyliden]iminooxy]aminopropanol Derivatives

D. Chiarino, F. Ferrario, M. Napoletano and A. Sala*

Zambon Group Research Laboratories, Bresso, Milan, Italy Received January 22, 1988

The preparation of new [[(3-substituted-5-isoxazolyl)alkyliden]iminooxy]aminopropanol compounds is reported starting from the corresponding 1-isoxazolylalkanones. The ¹H- and ¹³C-nmr studies, carried out to establish the Z- and E-configuration of new derivatives, are also described.

J. Heterocyclic Chem., 25, 1359 (1988).

In a previous paper [1] we described the synthesis and the pharmacological evaluation of a series of β_2 -adrenergic isoxazoles. Recently [2] we extended this study preparing a number of isoxazole aminoalcohols bearing substituents different from the previously reported [1] 3-halo and 3-alkoxy groups. In the past few years Lecrerc and coworkers reported the synthesis of oxime derivatives [3,4,5] having a marked β -blocking activity. Their data showed that the intercalation of an iminic function in the side chain of the β -blockers leads, in some cases, to potent and selective β_2 -agonists.

In continuing our program of synthesis and utilization of potentially active β -adrenergic isoxazoles, we prepared new aromatic oxymino derivatives **4a-h** which presented

the isoxazole nucleus as aromatic moiety.

Scheme 1 illustrates the synthetic approach used for the preparation of alkylaminopropanol derivatives 4a-f. Known ketones 1a-c [6,7] were treated with hydroxylamine hydrochloride and sodium acetate in aqueous ethanol at reflux to give already described oxime 2a [6] and new oximes 2b-c. Analytical data of derivatives 2b-c are presented in the experimental and ¹H-nmr data of compounds 2a-c are shown in Table 1.

It was reported [6] that the action of hydroxylamine on ketone **la** under basic conditions gave a mixture of Z- and **E**-oxime derivatives in a ratio of ca. 20:80 after crystallization from water. The same authors confirmed in a following paper [8] the configuration of Z- and E-isomers of ox-

Table 1 'H-NMR Data of Compounds **2a-c** and **4a-h**

Compound	δ (ppm), DMSO-d ₆
2a	12.10 and 12.00 (s, 0.02 and 0.98H), 7.21 and 6.53 (s, 0.02 and 0.98H), 3.95 and 3.90 (s, 0.06 and 2.94H), 2.16 and 2.08 (s, 0.06 and 2.94H)
2b	12.34 and 12.23 (s, 0.01 and 0.99H), 7.40 and 7.13 (s, 0.01 and 0.99H), 2.22 and 2.12 (s, 0.03 and 0.97H)
2 c	12.39 and 12.19 (s, 0.26 and 0.74H), 7.40 and 7.15 (s, 0.26 and 0.74H), 2.60 (m, 2H), 1.54 (m, 2H), 0.93 and 0.89 (t, 0.78 and 2.22H)
4a	9.09 (s broad, 1H), 8.73 (s broad, 1H), 6.97 and 6.69 (s, 0.18 and 0.82H), 5.87 and 5.81 (d, 0.18 and 0.82H), 4.18 (m, 3H), 3.95 and 3.91 (s, 0.54 and 2.46H), 3.31 (septet, 1H), 2.94 (m, 2H), 2.19 and 2.16 (s, 0.54 and 2.46H), 1.26 and 1.25 (d, 2.46 and 0.54H), 1.24 and 1.23 (d, 2.46 and 0.54H)
4 b	9.14 (s broad, 1H), 8.60 (s broad, 1H), 6.97 and 6.69 (s, 0.1 and 0.9H), 5.87 and 5.82 (d, 0.1 and 0.9H), 4.19 (m, 3H), 3.95 and 3.91 (s, 0.3 and 2.7H), 2.92 (m, 2H), 2.20 and 2.16 (s, 0.3 and 2.7H), 1.30 and 1.19 (s, 8.1 and 0.9H)
4 c	9.00 (s broad, 1H), 8.69 (s broad, 1H), 7.53 and 7.29 (s, 0.14 and 0.86H), 5.87 and 5.82 (d, 0.14 and 0.86H), 4.20 (m, 3H), 3.31 (septet, 1H), 2.96 (m, 2H), 2.26 and 2.20 (s, 0.42 and 2.58H), 1.25 (d, 3H), 1.23 (d, 3H)
4 d	9.11 (s broad, 1H), 8.59 (s broad, 1H), 7.54 and 7.29 (s, 0.16 and 0.84H), 5.89 and 5.83 (d, 0.16 and 0.84H), 4.21 (m, 2H), 4.20 (m, 1H), 2.92 (m, 2H), 2.26 and 2.20 (s, 0.48 and 2.52H), 1.30 (s, 9H)
4e	10.14 (s, 1H), 7.83 (m, 2H), 7.60 (m, 2H), 7.49 and 7.27 (s, 0.14 and 0.86H), 4.17 (d, 2H), 4.00 (m, 1H), 2.97 (septet, 1H), 2.71 (m, 4H), 2.06 (s, 3H), 1.53 (m, 2H), 1.09 (d, 3H), 0.90 and 0.89 (t, 0.42 and 2.58H)

4g 10.95 (d, 1H), 10.18 (s, 1H), 7.87 (m, 2H), 7.64 (m, 2H), 7.55 (d, 1H), 7.48 and 7.24 (s, 0.09 and 0.91H), 7.33 (dd, 1H), 7.19 (d, 1H), 7.01 (m, 2H), 4.22 (m, 2H), 3.99 (m, 1H), 2.89 (s, 2H), 2.82 (m, 2H), 2.25 and 2.18 (s, 0.27 and 2.73H), 2.07 (s, 3H), 1.10 (s, 3H), 1.08 (s, 3H)

2H), 2.05 (s, 3H), 1.54 (m, 2H), 1.09 (s, 9H), 0.90 and 0.89 (t, 0.69 and 2.31H)

10.11 (s, 1H), 7.83 (m, 2H), 7.60 (m, 2H), 7.50 and 7.27 (s, 0.23 and 0.77H), 4.20 (d, 2H), 4.04 (m, 1H), 2.79 (m, 2H), 2.63 (m,

4h 10.21 (s, 1H), 7.86 (m, 2H), 7.65 (m, 2H), 7.47 and 7.23 (s, 0.21 and 0.79H), 6.84 (d, 1H), 6.82 (d, 1H), 6.71 (dd, 1H), 4.16 (m, 2H), 3.93 (m, 1H), 3.72 (s, 3H), 3.70 (s, 3H), 2.89-2.59 (m, 6H), 2.24 and 2.17 (s, 0.63 and 2.37H), 2.07 (s, 3H)

Scheme 1

The geometry of Z- and E-forms of new derivatives 2b-c was unambiguously established by 'H-nmr spectra (Table 2) according with the data reported for compound 2a [8]. In fact we verified that the deshielding effect of the oxygen of the oxymino group when it is closed to the isoxazole ring (Z-isomerism), causes a down-field shift of the isoxazole proton at 4 position. Sodium salts of derivatives 2a-c were treated in N,N-dimethylformamide with epibromohy-

4g

drin affording intermediates 3a-c which were directly transformed into desired compounds 4a-f. The synthesis of aminoalcohols 4a-f was carried out in refluxing ethanol using a ten fold excess of the appropriate amine. Analytical data of derivatives 4a-f are illustrated in Table 3, ¹H-nmr data of these molecules are reported in Table 1.

Scheme 2 shows the last step of the synthetic approach used for the preparation of compounds 4g-h.

Crude intermediate 3b was treated in refluxing ethanol with a stoichiometric amount of 3-(2-amino-2-methylpropyl)indole and 2-(3,4-dimethoxyphenyl)ethylamine respectively. The choice of indolyl t-butylamine and phenethylamine as basic moieties was made on the base of interesting literature results [9,10] in the field of β -blocking agents. Analytical data of compounds 4g-h are presented in the experimental section, 'H-nmr data of these molecules are shown in Table 1.

It is interesting to note that compounds 4a-h were obtained as a mixture of Z- and E-isomers after crystallization of their salts. The geometry of the two isomers was established by 'H-nmr spectra (Table 2) compared with 'H-nmr data of the mixture of Z- and E-forms of oximes 2a-c. In Table 2 it is also indicated the ratio between Z-and E-isomers of aminoalcohols 4a-d. As expected, also starting from practically pure E-isomers 2a-b, a mixture of both possible isomers of compounds 4a-d and 4g-h was obtained. This is due to the oximate anion which would exist in solution as an equilibrium mixture of Z- and E-forms.

In order to complete the nmr study of the geometry of new compounds **4a-h**, we recorded a ¹³C-nmr spectrum of a representative derivative. The ¹³C chemical shifts of the two isomers of selected compound **4c** are illustrated in Table 4.

Scheme 2

Table 2

'H-NMR Study of Z- and E-Isomers of Compounds 2a-c and 4a-h

Compound	Ratio						
•	Z:E	Isoxazol	e proton	pical Signals, δ (ppm), DMSO-d ₆ $N = C - CH_3$		$N = C - (CH_2)_2 - CH_3$	
		Z	E	Z	E	Z	E
2a	2:98	7.21	6.53	2.16	2.08		
2 b	1:99	7.40	7.13	2.22	2.12		
2 c	26:74	7.40	7.15			0.93	0.89
4a	18:82	6.97	6.69	2.19	2.16		
4 b	10:90	6.97	6.69	2.20	2.16		
4c	14:86	7.53	7.29	2.26	2.20		
4d	16:84	7.54	7.29	2.26	2.20		
4e	14:86	7.49	7.27			0.90	0.89
4f	23:77	7.50	7.27			0.90	0.89
4g	9:91	7.48	7.24	2.25	2.18		
4h	21:79	7.47	7.23	2.24	2.27		


Table 3
Compounds 4a-f

Compound	R,	R ₂	R_3	Yield [a], %	Mp, °C [b]	Molecular Formula	Analysis, % (Calcd./Found)		
compound			,	(),			C	Н	N
4a	CH ₃ O	CH ₃	i-C ₃ H ₇	51	167-168	C ₁₂ H ₂₁ N ₃ O ₄ HCl	46.83 46.89	7.20 7.37	13.65 13.51
4b	CH ₃ O	СН₃	t-C ₄ H ₉	69	131-132	$C_{13}H_{23}N_3O_4$ HCl	48.52 48.54	7.52 7.66	13.06 12.97
4 c	Br	CH ₃	i-C ₃ H ₇	42	124-125	C ₁₁ H ₁₈ BrN ₃ O ₃ HCl	37.04 37.21	5.37 5.46	11.78 11.78
4d	Br	CH ₃	t-C ₄ H ₉	51	128-129	C ₁₂ H ₂₀ BrN ₃ O ₃ HCl	38.88 38.82	5.71 5.86	11.34 11.28
4e	Br	n-C ₃ H ₇	i-C ₃ H ₇	53	98-99	$C_{13}H_{22}BrN_3O_3H_2O$ $C_9H_9NO_3$ [c]	48.44 48.51	6.10 6.20	10.27 10.26
4f	Br	n-C ₃ H ₇	t-C ₄ H ₉	61	166-167	C ₁₄ H ₂₄ BrN ₃ O ₃ C ₂ H ₂ NO ₂ [c]	51.02 51.21	6.14 6.22	10.35 10.53

[[]a] Yields calculated from 2a-c. [b] Crystallization solvent: acetonitrile. [c] 4-Acetaminobenzoic acid.

Table 4

13C-NMR Data of Compound 4c



[a] Measured in DMSO-d6.

New aminoalcohols **4a-h** were tested for their potential β -adrenergic activity; the biological results will be published elsewhere.

EXPERIMENTAL

Melting points were determined on a Buchi SMP-20 apparatus and are uncorrected, boiling point of compound 2c is also uncorrected. The 'H-nmr and '3C-nmr spectra were recorded with a Varian Gemini 200.

3-Bromo-5-(1-hydroxyiminoethyl)isoxazole 2b.

A mixture of 1b (15.1 g, 0.0795 mole), sodium acetate trihydrate (12.44 g, 0.0914 mole) and hydroxylamine hydrochloride (6.35 g, 0.0914 mole) in 50% aqueous ethanol (100 ml) was refluxed for 1 hour. After evaporation of the solvent (50 ml), the resulting solid was collected and crystallized from water to give pure 2b (14.6 g, 90%, mp 158-159°).

Anal. Calcd. for $C_5H_5BrN_2O_5$: \overline{C} , 29.29; \overline{H} , 2.46; \overline{N} , 13.66. Found: \overline{C} , 29.41; \overline{H} , 2.50; \overline{N} , 13.58.

3-Bromo-5-(1-hydroxyiminobutyl)isoxazole 2c.

Compound 2c was similarly prepared as a colorless oil in a yield of 95% (135-140°, 0.6 torr).

Anal. Calcd. for $C_7H_9BrN_2O_2$: C, 36.07; H, 3.89; N, 12.02. Found: C, 36.21; H, 3.83; N, 11.96.

1-[[1-(3-Bromo-5-isoxazoly)-1-ethyliden]iminooxy]-3-isopropylamino-2-propanol Hydrochloride 4c.

To a stirred solution of 2b (6.15 g, 0.03 mole) in N,N-dimethylformamide (30 ml), 80% sodium hydride suspension in mineral oil (0.9 g, 0.03 mole) was added portionwise at 0°. The obtained yellow solution was dropped at 15° to a stirred solution of epibromohydrin (4.1 g, 0.03 mole) in N.N-dimethylformamide (20 ml). After stirring overnight, the mixture was poured into water (200 ml) and extracted twice with chloroform. The organic layer was separated, washed with water, dried and evaporated to give crude 3b as an oil. To a stirred solution of crude 3b in ethanol (37 ml) a solution of isopropylamine (25.8 ml, 0.3 mole) in ethanol (60 ml) was added dropwise at 80° and the resulting mixture was refluxed overnight. The solvent was evaporated and the residue was treated with 2N hydrochloric acid and chloroform. The aqueous layer was separated and basified with potassium carbonate and the mixture was extracted with ethyl ether. The organic layer was separated, washed with water, dried and treated with a solution of hydrochloric acid in ethyl ether. The resulting solid was collected and crystallized from acetonitrile to give pure 4c (4.5 g, 42%, mp 124-125°).

Compounds 4a-b and 4d-f, listed in Table 3, were similarly prepared.

1-[[1-(3-Bromo-5-isoxazolyl)-1-ethyliden]iminooxy]-3-[2-methyl-3-(3-indolyl)-2-propylamino]-2-propanol 4-Acetaminobenzoate 4g.

To a stirred solution of crude 3b (0.03 mole, prepared as described for compound 4c) in ethanol (78 ml), a solution of 3-(2-amino-2-methylpropyl)indole [9] (5.65 g, 0.03 mole) in ethanol (56 ml) was added dropwise at 80° and the resulting mixture was refluxed overnight. The solvent was evaporated and the residue was treated with water and chloroform. The organic layer was separated, washed with water, dried and evaporated. The oily residue was purified by column chromatography (silica gel 500 g, eluent chloroform-methanol-ammonium hydroxide 95-5-0.5) to give a pure oil (8.1 g, 0.018 mole) which was dissolved in ethanol (120 ml) and treated with 4-acetaminobenzoic acid (3.23 g, 0.018 mole). After evaporation of the solvent, the solid residue was crystallized from ethyl acetate to give pure 4g (10.0 g, 53%, mp 120-121°).

Anal. Calcd. for $C_{29}H_{34}BrN_5O_6$: C, 55.42; H, 5.45; N, 11.14. Found: C, 55.27; H, 5.40; N, 11.01.

1-[[1-(3-Bromo-5-isoxazolyl)-1-ethyliden]iminooxy]-3-[2-(3,4-dimethoxy-phenyl)ethylamino]-2-propanol 4-Acetaminobenzoate 4h.

Compound 4h was similarly prepared as a solid in a yield of 55% (mp 105-106° from ethyl acetate).

Anal. Calcd. for $C_{27}H_{33}BrN_4O_8$: C, 52.18; H, 5.35; N, 9.01. Found: C, 52.28; H, 5.29; N, 8.92.

REFERENCES AND NOTES

- [1] D. Chiarino, M. Fantucci, A. Carenzi, D. Della Bella, V. Frigeni and R. Sala, Farmaco, Ed. Sci., 41, 440 (1986).
- [2] D. Chiarino, M. Fantucci, A. Sala and C. Veneziani, J. Heterocyclic Chem., 25, 337 (1988).
- [3] G. Lecrerc, A. Mann, C. Wermuth, N. Bieth and J. Schwartz, J. Med. Chem., 20, 1657 (1977).
- [4] G. Lecrerc, N. Bieth and J. Schwartz, J. Med. Chem., 23, 620 (1980).
- [5] M. Bouzoubaa, G. Lecrerc, N. Decker, J. Schwartz and G. Andermann, J. Med. Chem., 27, 1291 (1984).
- [6] P. Krogsgaard-Larsen and S. Christensen, Acta Chem. Scand B, 28, 636 (1974).
- [7] D. Chiarino, M. Napoletano and A. Sala, J. Heterocyclic Chem., 24, 43 (1987).
- [8] S. Christensen and P. Krogsgaard-Larsen, Acta Chem. Scand. B, 29, 65 (1975).
- [9] W. Krieghbann, L. Matier, R. Dennis, J. Minielli, D. Deitchman, J. Perhach and W. Comer, J. Med. Chem., 23, 285 (1980).
- [10] M. Hoefle, S. Hastings, R. Meyer, R. Corey, A. Holmen and C. Stratton, *J. Med. Chem.*, 18, 148 (1975).